Acute effects of intravenous fasudil with different dosage on patients with congenital heart defects and severe pulmonary arterial hypertension

• Published in: Zhong hua yi xue za zhi Vol. 98; no. 9; p. 678
• Main Authors: Ruan, H Y, Zhang, Y G, Liu, R
• Format: Journal Article
• Language: Chinese
• Published: China 06.03.2018
• Subjects: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine - analogs & derivatives; Adult; Familial Primary Pulmonary Hypertension; Heart Defects, Congenital; Hemodynamics; Humans; Hypertension, Pulmonary; Middle Aged; Young Adult; Rho-kinase inhibitor; Pulmonary arterial hypertension; Congenital heart defects; Fasudil
• ISSN: 0376-2491
• DOI: 10.3760/cma.j.issn.0376-2491.2018.09.011

To compare the acute hemodynamic effects of intravenous fasudil with different dosage on patients with congenital heart defects (CHD) and severe pulmonary arterial hypertension (PAH). Sixty patients (37±17 years old) with CHD and PAH were consecutively enrolled. All patients underwent heart catheterization. The patients were randomly divided into two groups: the regular dosage group and the large dosage group. At initiation and 30 min after intravenous fasudil(30 mg and 60 mg respectively), the following hemodynamic parameters were measured and calculated: right atrial pressure(RAP), pulmonary arterypressure(PAP) , systemic artery pressure (SAP), pulmonary capillary wedge pressure(PCWP) , pulmonary vascular resistance(PVR) and systemic vascular resistance( SVR), cardiac index (CI) and artery oxygen saturation (SaO(2)). Compared with pre-medication, both mPAP and PVR tended to reduce significantly in the regular dosage group and the large dosage group: mPAP from (63.7±8.6)to (58.3±8.5)mmHg( <0.01) and from (62